Publications in collaboration with researchers from Hospital Universitario Puerta de Hierro (17)

2024

  1. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466

  2. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-Related Cancer, Vol. 31, Núm. 7

2021

  1. Craniopharyngioma in the Elderly: A Multicenter and Nationwide Study in Spain

    Neuroendocrinology, Vol. 111, Núm. 10, pp. 925-936

  2. Erratum: Late Recovery of Parathyroid Function after Total Thyroidectomy: A Case-Control Study (Horm Metab Res (2021) 53 DOI: 10.1055/a-1608-1373)

    Hormone and Metabolic Research

  3. Late Recovery of Parathyroid Function after Total Thyroidectomy: A Case-Control Study

    Hormone and Metabolic Research, Vol. 53, Núm. 10, pp. 654-661

2020

  1. Permanent postoperative hypoparathyroidism: an analysis of prevalence and predictive factors for adequacy of control in a cohort of 260 patients

    Gland Surgery, Vol. 9, Núm. 5, pp. 1380-1388

2019

  1. ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly

    Endocrinologia, Diabetes y Nutricion, Vol. 66, Núm. 5, pp. 320-329

  2. Correction to: Prevalence and risk factors for hypoparathyroidism following total thyroidectomy in Spain: a multicentric and nation-wide retrospective analysis (Endocrine, (2019), 66, 2, (405-415), 10.1007/s12020-019-02014-8)

    Endocrine

  3. Posterior pituitary tumours: the spectrum of a unique entity. A clinical and histological study of a large case series

    Endocrine, Vol. 63, Núm. 1, pp. 36-43

  4. Prevalence and risk factors for hypoparathyroidism following total thyroidectomy in Spain: a multicentric and nation-wide retrospective analysis

    Endocrine, Vol. 66, Núm. 2, pp. 405-415

2016

  1. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study

    Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 63, Núm. 8, pp. 397-408

2014

  1. Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study

    Clinical Endocrinology, Vol. 81, Núm. 6, pp. 883-890

2004

  1. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA)

    European Journal of Endocrinology, Vol. 151, Núm. 4, pp. 439-446

1994

  1. Usefulness of thyrotropin-releasing hormone test, SMS 201–995, and bromocriptine in the diagnosis and treatment of gonadotropin-secreting pituitary adenomas

    Journal of Endocrinological Investigation, Vol. 17, Núm. 2, pp. 99-104

1993

  1. A malignant extra-adrenal pheochromocytoma. Apropos 2 cases

    Revista clínica española, Vol. 192, Núm. 2, pp. 76-78

  2. Anterior pituitary function after adrenalectomy in patients with Cushing's syndrome

    Postgraduate Medical Journal, Vol. 69, Núm. 813, pp. 547-551

1991

  1. Results of external pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease

    Acta Endocrinologica, Vol. 125, Núm. 5, pp. 470-474